PGY2 Oncology Pharmacy Resident Memorial Sloan Kettering Cancer Center New York, New York, United States
Poster Abstract:
Background: Lung cancer remains a leading cause of morbidity and mortality in the United States, with non-small cell lung cancer (NSCLC) comprising a significant majority of cases. Among NSCLC cases, those harboring MET exon 14 skipping mutations or MET amplifications have historically faced limited treatment options. However, recent advancements have led to the approval of two MET-specific tyrosine kinase inhibitors (TKIs), capmatinib and tepotinib. Despite their approval and incorporation into treatment guidelines, there is a notable absence of head-to-head comparative studies assessing their real-world clinical outcomes. This study aims to address this gap by evaluating and comparing the efficacy and safety of capmatinib and tepotinib in patients with MET-altered NSCLC.
Objectives: The primary objective of this research is to compare the real-world clinical outcomes of capmatinib and tepotinib therapy in patients with NSCLC exhibiting MET exon 14 skipping mutations or MET amplifications. The primary clinical outcomes to be assessed will be progression-free survival (PFS) and overall survival (OS). Secondary outcomes include overall response rate (ORR), time to next treatment, duration of response, presence and development of brain metastases, and duration of treatment. Additionally, safety parameters such as weight, albumin levels, liver function tests, serum creatinine levels, complete blood counts, dose modifications, and other reported adverse effects will be evaluated.
Methods: This single-center, retrospective, IRB-approved study will involve a chart review of patients aged 18 or older with locally advanced or metastatic NSCLC and confirmed MET exon 14 skipping mutations or MET amplifications. The study will include patients treated at MSKCC from May 1, 2020, to June 26, 2023. Inclusion criteria involve patients treated with capmatinib or tepotinib. Exclusion criteria involve prior treatment with crizotinib, cabozantinib, or any other MET-driven therapy, as well as the presence of other oncogenic driver mutations or acquired MET mutations through secondary resistance mechanisms. Data collection will include baseline characteristics, dosages of MET-specific agents, and pathological features including type of MET alterations obtained from existing next-generation sequencing data, thus enabling a comprehensive analysis of real-world outcomes for these two MET-specific TKIs. Descriptive statistics will be used to assess demographic information, proportion estimates for ORR, and Kaplan Meier curves for survival outcomes.
Results: Out of 114 records reviewed, 57 patients met criteria for inclusion. Further esults are pending.
Conclusion: Conclusions are pending.
References (must also be included in final poster): 1. Lung cancer statistics: How common is lung cancer? Lung Cancer Statistics | How Common is Lung Cancer? | American Cancer Society. Accessed July 20, 2023. https://www.cancer.org/cancer/types/lung-cancer/about/key-statistics.html. 2. Socinski MA, Pennell NA, Davies KD. MET Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations. JCO Precis Oncol. 2021;5:PO.20.00516. Published 2021 Apr 13. doi:10.1200/PO.20.00516 3. Wolf J, Seto T, Han JY, et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020;383(10):944-957. doi:10.1056/NEJMoa2002787 4. Paik PK, Felip E, Veillon R, et al. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med. 2020;383(10):931-943. doi:10.1056/NEJMoa2004407 5. National Comprehensive Cancer Network. Non-Small Cell Lung Cancer (Version 5.2023).
